Form 4: Sutro Biopharma CFO Edward Albini Reports Stock Transactions

Sentiment:

SEC Form 4 Filing


CFO and Secretary of Sutro Biopharma, Edward Albini, reports the vesting and withholding of shares to cover tax obligations.

Summary

  • On March 4, 2024, Edward Albini, CFO and Secretary of Sutro Biopharma, engaged in transactions involving the company's common stock and restricted stock units (RSUs).
  • Albini acquired 9,125 shares of common stock through the vesting of RSUs.
  • 3,472 shares were withheld by the issuer to satisfy income tax obligations related to the RSU settlement at a price of $4.79 per share.
  • Following these transactions, Albini directly owns 101,093 shares of Sutro Biopharma common stock and 18,250 RSUs.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions, with no inherent positive or negative sentiment.

Industry Context

Form 4 filings are a routine part of compliance for company insiders and provide transparency into their transactions in company stock.

Key Dates

DateDescription
03/04/2023RSUs vest as to 1/4th of the total award annually beginning on this date.
03/04/2024Date of transactions: RSU vesting and tax withholding.
03/04/2026RSU Expiration Date
03/06/2024Date of signature on the Form 4 filing.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.